DelveInsight has launched a new report on Focal Segmental Glomerulosclerosis Epidemiology and Market Forecast-2030
DelveInsight’s ‘Focal Segmental Glomerulosclerosis (FSGS) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Focal Segmental Glomerulosclerosis (FSGS) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
The Focal Segmental Glomerulosclerosis (FSGS) epidemiology covered in the report provides historical as well as forecasted Focal Segmental Glomerulosclerosis (FSGS) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
The DelveInsight Focal Segmental Glomerulosclerosis (FSGS) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
Report Key facts:-
1. Age plays important role in the prevalence of FSGS. As per DelveInsight estimates, there were 4,306 cases of children with FSGS, while adults contribute 8,613 cases of FSGS in 2017 for Germany.
2. In 2017, there were 45,852 prevalent cases of FSGS in males and 34,731 cases in females and as per analyst assessments, the overall cases of FSGS in both the genders is subjected to increase in the coming years in 7MM.
“According to DelveInsight’s analysis, Male cases of FSGS are more prominent in comparison to Female”
Key companies are working on FSGS are given below:-
1. Retrophin Pharma Co
2. Dimerix Pharma Co.
3.Aurinia Pharmaceuticals.
Name of drugs covered that are given below:-
1. Sparsentan2. DMX-2003. Voclosporin
Table of contents
1. Key Insights
2. Executive Summary of Focal Segmental Glomerulosclerosis (FSGS)
3. Focal Segmental Glomerulosclerosis (FSGS): Disease Background and Overview
4. Patient Journey
5. Epidemiology and Patient Population
6. Treatment Algorithm, Current Treatment, and Medical Practices
6.1. Focal Segmental Glomerulosclerosis (FSGS) Treatment and Management
6.2. Focal Segmental Glomerulosclerosis (FSGS) Treatment Algorithm
7. KOL Views
8. Unmet Needs
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
Why should you buy this report?
Related Reports :-
1. Focal Segmental Glomerulosclerosis (FSGS)- Market Insight, Epidemiology and Market Forecast -2030
2. Focal Segmental Glomerulosclerosis (FSGS) – Pipeline Insights, 2020
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/